Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Portfolio Pulse from Vandana Singh
Pharmaceutical companies, including Johnson & Johnson, Merck & Co Inc, and Halozyme Therapeutics Inc, anticipate that reformulated injectable versions of some popular treatments will not be included in U.S. government price negotiations for several years, safeguarding substantial revenue. They argue that modifying the formula of intravenous medications to allow for injectable use qualifies them as new drugs, delaying their price negotiation eligibility. Bristol Myers Squibb & Co and Roche Holdings AG, developing under-the-skin injections of cancer immunotherapies, stated that it's premature to comment.
July 28, 2023 | 5:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics Inc is licensing hyaluronidase, the essential ingredient for subcutaneous medications.
The news is directly related to Halozyme Therapeutics and their licensing of hyaluronidase. The potential exclusion from price negotiations could safeguard substantial revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Johnson & Johnson anticipates that their subcutaneous Darzalex variant, Darzalex Faspro, will not be eligible for negotiation until 2033 or 2034.
The news is directly related to Johnson & Johnson and their product Darzalex Faspro. The potential exclusion from price negotiations could safeguard substantial revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck plans to launch its Keytruda injectable within a few years.
The news is directly related to Merck and their product Keytruda. The potential exclusion from price negotiations could safeguard substantial revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Bristol Myers Squibb & Co stated that it's premature to comment on the development of under-the-skin injections of cancer immunotherapies.
The news mentions Bristol Myers Squibb & Co, but the company has not provided a clear stance on the issue. The potential impact on the company is uncertain at this time.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
NEUTRAL IMPACT
Roche Holdings AG stated that it's premature to comment on the development of under-the-skin injections of cancer immunotherapies.
The news mentions Roche Holdings AG, but the company has not provided a clear stance on the issue. The potential impact on the company is uncertain at this time.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80